BG106104A - Method for the treatment of diseases related to increased number of neutrophils or neutrophil overactivation - Google Patents

Method for the treatment of diseases related to increased number of neutrophils or neutrophil overactivation

Info

Publication number: BG106104A
Authority: BG; Bulgaria
Prior art keywords: overactivation; neutrophil; neutrophils; treatment; increased number
Prior art date: 1999-04-15

Application number

BG106104A

Other languages

Bulgarian (bg)

English (en)

Inventor

Colin MACPHEE

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-04-15

Filing date

2001-11-13

Publication date

2002-05-31

2001-11-13 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

2002-05-31 Publication of BG106104A publication Critical patent/BG106104A/xx

Links

210000000440 neutrophil Anatomy 0.000 title 2
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
231100000252 nontoxic Toxicity 0.000 abstract 1
230000003000 nontoxic effect Effects 0.000 abstract 1

Classifications

- G—PHYSICS
- G11—INFORMATION STORAGE
- G11B—INFORMATION STORAGE BASED ON RELATIVE MOVEMENT BETWEEN RECORD CARRIER AND TRANSDUCER
- G11B20/00—Signal processing not specific to the method of recording or reproducing; Circuits therefor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
Rheumatology (AREA)
Hematology (AREA)
Neurology (AREA)
Virology (AREA)
Endocrinology (AREA)
Communicable Diseases (AREA)
Urology & Nephrology (AREA)
Neurosurgery (AREA)
Tropical Medicine & Parasitology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Biomedical Technology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Ophthalmology & Optometry (AREA)
Molecular Biology (AREA)

BG106104A 1999-04-15 2001-11-13 Method for the treatment of diseases related to increased number of neutrophils or neutrophil overactivation BG106104A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9908647.2A GB9908647D0 (en)	1999-04-15	1999-04-15	Novel compounds
PCT/GB2000/001499 WO2000062766A2 (en)	1999-04-15	2000-04-17	Uses of ppar-gamma agonists in neutrophil-induced diseases

Publications (1)

Publication Number	Publication Date
BG106104A true BG106104A (en)	2002-05-31

Family

ID=10851605

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG106104A BG106104A (en)	1999-04-15	2001-11-13	Method for the treatment of diseases related to increased number of neutrophils or neutrophil overactivation

Country Status (32)

Country	Link
EP (2)	EP1274407B1 (pl)
JP (1)	JP2003516310A (pl)
KR (1)	KR20010108506A (pl)
CN (1)	CN1413105A (pl)
AP (1)	AP2001002291A0 (pl)
AT (1)	ATE319437T1 (pl)
AU (1)	AU4583000A (pl)
BG (1)	BG106104A (pl)
BR (1)	BR0009776A (pl)
CA (1)	CA2370127A1 (pl)
CZ (1)	CZ20013688A3 (pl)
DE (1)	DE60026508T2 (pl)
DK (1)	DK1274407T3 (pl)
DZ (1)	DZ3151A1 (pl)
EA (1)	EA200101089A1 (pl)
ES (1)	ES2256003T3 (pl)
GB (1)	GB9908647D0 (pl)
HK (1)	HK1053788A1 (pl)
HR (1)	HRP20010746A2 (pl)
HU (1)	HUP0300479A2 (pl)
ID (1)	ID30339A (pl)
IL (1)	IL145875A0 (pl)
MA (1)	MA25351A1 (pl)
MX (1)	MXPA01010428A (pl)
NO (1)	NO20014950L (pl)
PL (1)	PL364720A1 (pl)
PT (1)	PT1274407E (pl)
SK (1)	SK14532001A3 (pl)
TR (1)	TR200102977T2 (pl)
WO (1)	WO2000062766A2 (pl)
YU (1)	YU77901A (pl)
ZA (1)	ZA200108446B (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9913782D0 (en) *	1999-06-14	1999-08-11	Smithkline Beecham Plc	Novel compounds
EP1331934B1 (de) *	2000-11-09	2006-03-29	Phenion GmbH & Co KG	Ppar-alpha,beta-aktivatoren zur behandlung von alopecia areata und vitiligo
GB0030845D0 (en) *	2000-12-18	2001-01-31	Smithkline Beecham Plc	Novel treatment
GB2373725A (en) *	2001-03-30	2002-10-02	Novartis Ag	Use of a PPAR gamma agonist in the production of a medicament for the prevention or treatment of diseases associated with IL-10 production
AU2002343094A1 (en) *	2001-11-26	2003-06-10	Arachnova Therapeutics Ltd.	Use of ppar activators for the treatment of pulmonary fibrosis
DE10204398A1 (de) *	2002-02-04	2003-08-14	Univ Goettingen Georg August	Neue Verwendung von Liganden der 'Peroxisome Proliferator-Activated receptors'(PPAR)
US6992093B2 (en)	2002-05-02	2006-01-31	Los Angeles Biomedical Research Institute At Harbor Ucla Medical Center	Method of inhibiting lipofibroblast to myofibroblast transdifferentiation
US8293479B2 (en)	2002-05-02	2012-10-23	Los Angeles Biomedical Research Institute At Harbor Ucla Medical Center	Use of parathyroid hormone-related protein(PTHRP) in the diagnosis and treatment of chronic lung disease and other pathologies
US20030220300A1 (en) *	2002-05-14	2003-11-27	Hwang Cheng Shine	Reduction of hair growth
ITRM20050389A1 (it)	2005-07-22	2007-01-23	Giuliani Spa	Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
KR101333089B1 (ko)	2006-05-22	2013-11-27	재단법인 아산사회복지재단	로지글리타존을 유효성분으로 함유하는 흡연-유발 만성폐쇄성 폐질환 예방 또는 치료용 약제학적 조성물
DK2222272T3 (da) *	2008-08-07	2013-02-11	Pulmagen Therapeutics Inflammation Ltd	Behandling af luftvejssygdom
GB0913672D0 (en)	2009-08-05	2009-09-16	Argenta Discovery Ltd	Glitazones
US8236786B2 (en)	2008-08-07	2012-08-07	Pulmagen Therapeutics (Inflammation) Limited	Respiratory disease treatment
UA107562C2 (uk)	2008-12-05	2015-01-26		Спосіб лікування псоріазу
SI2379507T1 (sl)	2008-12-30	2014-02-28	Pulmagen Therapeutics (Inflammation) Limited	Spojine sulfonamida za zdravljenje respiratornih motenj
LT2396081T (lt)	2009-02-16	2017-09-11	Nogra Pharma Limited	Alkilamido junginiai ir jų panaudojimas
WO2010150014A1 (en)	2009-06-24	2010-12-29	Pulmagen Therapeutics (Inflammation) Limited	5r- 5 -deuterated glitazones for respiratory disease treatment
WO2011098746A1 (en)	2010-02-09	2011-08-18	Pulmagen Therapeutics (Inflammation) Limited	Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002243D0 (en)	2010-02-10	2010-03-31	Argenta Therapeutics Ltd	Respiratory disease treatment
GB201002224D0 (en)	2010-02-10	2010-03-31	Argenta Therapeutics Ltd	Respiratory disease treatment
AU2013217933B2 (en)	2012-02-09	2017-11-30	Nogra Pharma Limited	Methods of treating fibrosis
AU2013248397A1 (en)	2012-04-18	2014-10-02	Nogra Pharma Limited	Methods of treating lactose intolerance
WO2016040313A2 (en) *	2014-09-08	2016-03-17	Dana-Farber Cancer Institute, Inc.	Methods of treating cancer
RU2742417C1 (ru) *	2017-01-13	2021-02-05	Тобиси Фармасьютикал Ко., Лтд.	Регулятор активации нейтрофилов
AU2020217884B2 (en)	2019-02-08	2025-02-20	Nogra Pharma Limited	Process of making 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof
JP2020145939A (ja) *	2019-03-12	2020-09-17	日本製粉株式会社	アレルギー性鼻炎抑制用組成物
CN116531374A (zh) *	2023-04-20	2023-08-04	中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所)	吡格列酮及其盐在制备用于治疗系统性红斑狼疮的产品中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9611947D0 (en) *	1996-06-07	1996-08-07	Glaxo Group Ltd	Medicaments
JPH10139665A (ja) *	1996-09-12	1998-05-26	Sankyo Co Ltd	トログリタゾンを含有するグルタチオン還元酵素活性増強剤
DE69726182T2 (de) *	1996-12-11	2004-08-12	Dana-Farber Cancer Institute, Inc., Boston	Methoden und pharmazeutische zusammenstellungen zur wachstumsverhinderung von tumorzellen enthaltend einen ppar-gamma agonisten und einen map kinase inhibitor
US6646008B1 (en) *	1996-12-31	2003-11-11	The Salk Institute For Biological Studies	Treatment of disease states which result from neoplastic cell proliferation using PPAR-γ activators and compositions useful therefor
FR2773075B1 (fr) *	1997-12-31	2000-05-05	Cird Galderma	Utilisation d'activateurs de ppar-gamma en dermatologie
US6028088A (en) *	1998-10-30	2000-02-22	The University Of Mississippi	Flavonoid derivatives

1999
- 1999-04-15 GB GBGB9908647.2A patent/GB9908647D0/en not_active Ceased
2000
- 2000-04-11 DZ DZ003151A patent/DZ3151A1/xx active
- 2000-04-17 HU HU0300479A patent/HUP0300479A2/hu unknown
- 2000-04-17 PL PL00364720A patent/PL364720A1/pl not_active Application Discontinuation
- 2000-04-17 MX MXPA01010428A patent/MXPA01010428A/es unknown
- 2000-04-17 AU AU45830/00A patent/AU4583000A/en not_active Abandoned
- 2000-04-17 YU YU77901A patent/YU77901A/sh unknown
- 2000-04-17 TR TR2001/02977T patent/TR200102977T2/xx unknown
- 2000-04-17 ID IDW00200102237A patent/ID30339A/id unknown
- 2000-04-17 CA CA002370127A patent/CA2370127A1/en not_active Abandoned
- 2000-04-17 PT PT00927425T patent/PT1274407E/pt unknown
- 2000-04-17 WO PCT/GB2000/001499 patent/WO2000062766A2/en not_active Ceased
- 2000-04-17 AP APAP/P/2001/002291A patent/AP2001002291A0/en unknown
- 2000-04-17 HR HR20010746A patent/HRP20010746A2/hr not_active Application Discontinuation
- 2000-04-17 BR BR0009776-4A patent/BR0009776A/pt not_active IP Right Cessation
- 2000-04-17 HK HK03104497.7A patent/HK1053788A1/zh unknown
- 2000-04-17 CN CN00809014A patent/CN1413105A/zh active Pending
- 2000-04-17 EA EA200101089A patent/EA200101089A1/ru unknown
- 2000-04-17 KR KR1020017013106A patent/KR20010108506A/ko not_active Ceased
- 2000-04-17 SK SK1453-2001A patent/SK14532001A3/sk unknown
- 2000-04-17 DK DK00927425T patent/DK1274407T3/da active
- 2000-04-17 AT AT00927425T patent/ATE319437T1/de not_active IP Right Cessation
- 2000-04-17 EP EP00927425A patent/EP1274407B1/en not_active Expired - Lifetime
- 2000-04-17 CZ CZ20013688A patent/CZ20013688A3/cs unknown
- 2000-04-17 IL IL14587500A patent/IL145875A0/xx unknown
- 2000-04-17 DE DE60026508T patent/DE60026508T2/de not_active Expired - Lifetime
- 2000-04-17 JP JP2000611903A patent/JP2003516310A/ja active Pending
- 2000-04-17 ES ES00927425T patent/ES2256003T3/es not_active Expired - Lifetime
- 2000-04-17 EP EP05076787A patent/EP1593379A3/en not_active Withdrawn
2001
- 2001-10-11 NO NO20014950A patent/NO20014950L/no not_active Application Discontinuation
- 2001-10-12 MA MA26355A patent/MA25351A1/fr unknown
- 2001-10-15 ZA ZA200108446A patent/ZA200108446B/xx unknown
- 2001-11-13 BG BG106104A patent/BG106104A/xx unknown

Also Published As

Publication number	Publication date
DE60026508T2 (de)	2006-11-16
JP2003516310A (ja)	2003-05-13
CZ20013688A3 (cs)	2003-03-12
PL364720A1 (pl)	2004-12-13
CN1413105A (zh)	2003-04-23
EA200101089A1 (ru)	2002-10-31
PT1274407E (pt)	2006-06-30
KR20010108506A (ko)	2001-12-07
ID30339A (id)	2001-11-22
BR0009776A (pt)	2002-06-04
NO20014950D0 (no)	2001-10-11
AU4583000A (en)	2000-11-02
DK1274407T3 (da)	2006-06-26
MXPA01010428A (es)	2002-05-06
YU77901A (sh)	2005-07-19
HK1053788A1 (zh)	2003-11-07
SK14532001A3 (sk)	2002-02-05
AP2001002291A0 (en)	2001-12-31
WO2000062766A2 (en)	2000-10-26
ES2256003T3 (es)	2006-07-16
GB9908647D0 (en)	1999-06-09
NO20014950L (no)	2001-12-13
DE60026508D1 (de)	2006-05-04
ATE319437T1 (de)	2006-03-15
MA25351A1 (fr)	2001-12-31
CA2370127A1 (en)	2000-10-26
EP1593379A2 (en)	2005-11-09
HUP0300479A2 (hu)	2003-07-28
ZA200108446B (en)	2003-08-27
TR200102977T2 (tr)	2002-09-23
EP1593379A3 (en)	2007-10-31
DZ3151A1 (fr)	2000-10-19
HRP20010746A2 (en)	2002-10-31
EP1274407B1 (en)	2006-03-08
IL145875A0 (en)	2002-07-25
EP1274407A2 (en)	2003-01-15
WO2000062766A3 (en)	2002-10-31

Publication	Publication Date	Title
AP2001002291A0 (en)	2001-12-31	Novel method of treatment.
MY115662A (en)	2003-08-30	Novel compounds with analgesic effect
MY119403A (en)	2005-05-31	Novel compounds with analgesic effect.
UA48946C2 (uk)	2002-09-16	Арилалкілдіазинони, спосіб їх одержання (варіанти), фармацевтичний склад, спосіб його одержання та спосіб лікування
MY132705A (en)	2007-10-31	Novel compounds with analgesic effect
GEP20022656B (en)	2002-03-25	2-(Purin-9-YL)-Tetrahydrofuran-3,4-Diol Derivatives
CY1107850T1 (el)	2013-06-19	Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
MY127126A (en)	2006-11-30	Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
GEP20043269B (en)	2004-06-25	Purine Derivatives, Method for Their Production and Composition Containing the Same
GEP20012388B (en)	2001-03-25	Metalloproteinase Inhibitors, Pharmaceutical Compositions on Their Base, Use and Methods for Obtaining and Intermediates
UA43391C2 (uk)	2001-12-17	Спосіб інгібування міжклітинного зчеплення і спосіб інгібування запального процесу та порушеного процесу нормальної коагуляції у пацієнтів з розладами васкулярного ендотелію
RU94044436A (ru)	1996-10-20	Способы подавления атрофии кожи и влагалища
MXPA05003302A (es)	2005-10-18	Compuestos de piperazina terapeuticos.
AU3850600A (en)	2000-10-04	Dalda analogs and their use
GEP20043383B (en)	2004-07-12	Cell Adhesion-Inhibiting Antiinflammatory and Immune-Suppressive Compounds
WO1992019617A3 (en)	1992-12-10	Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
MX9701360A (es)	1997-05-31	Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion.
RU94044454A (ru)	1996-10-10	Ингибитор аутоимунных заболеваний
GB0130677D0 (en)	2002-02-06	Medicaments and novel compounds
NZ513096A (en)	2003-01-31	Compositions for treating inflammatory response
ZA922297B (en)	1992-12-30	Crystalline tiababine monohydrate,its preparation and use
MXPA02012730A (es)	2003-05-14	Uso de acido pamoico o uno de sus derivados o uno de sus analogos para la preparacion de un medicamento para el tratamiento de enfermedades caracterizadas por depositos de agregados de amiloide.
SE9802209D0 (sv)	1998-06-22	Novel compounds
MY133169A (en)	2007-10-31	Substituted heterocyclic benzocycloalkenes and the use thereof as substances having an analgesic effect
MXPA04004826A (es)	2004-08-11	Antagonista del receptor de quimioquinas y metodos para su uso.